Alan W. Dunton, MD joined Purdue Pharma in November 2015 as Senior Vice President of Research & Development (R&D). His responsibilities include spearheading the Company’s overall research strategy and early clinical development programs. Dr. Dunton serves as the Company’s lead scientist and oversees the Medical Research, Drug Safety, Clinical Pharmacology, Virtual Discovery, Project Management and Pharmaceutics & Analytics teams. Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue Pharma. Prior to starting Danerius, Dr. Dunton held executive-level positions in the pharmaceutical and biotechnology industries, including President and Chief Executive Officer of Panacos Pharmaceuticals, and Metaphore Pharmaceuticals. He was also the President and Managing Director of the Janssen Research Foundation, the R&D arm of the pharmaceuticals division at Johnson & Johnson. During his career, he has been responsible for the approval of more than 20 prescription and OTC products. Alan W. Dunton, MD joined Purdue Pharma in November 2015 as Senior Vice President of Research & Development (R&D). His responsibilities include spearheading the Company’s overall research strategy and early clinical development programs. Dr. Dunton serves as the Company’s lead scientist and oversees the Medical Research, Drug Safety, Clinical Pharmacology, Virtual Discovery, Project Management and Pharmaceutics & Analytics teams. Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue Pharma. Prior to starting Danerius, Dr. Dunton held executive-level positions in the pharmaceutical and biotechnology industries, including President and Chief Executive Officer of Panacos Pharmaceuticals, and Metaphore Pharmaceuticals. He was also the President and Managing Director of the Janssen Research Foundation, the R&D arm of the pharmaceuticals division at Johnson & Johnson. During his career, he has been responsible for the approval of more than 20 prescription and OTC products.

Pharmaceutical industry